![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/1/1f/Otenzepad.svg/640px-Otenzepad.svg.png&w=640&q=50)
Otenzepad
Drug / From Wikipedia, the free encyclopedia
Otenzepad is a competitive muscarinic receptor antagonist that is relatively selective at the M2 receptor. It was investigated as a treatment for arrhythmia and bradycardia due to its cardioselectivity but research ceased after stage III clinical trials. The drug was originally developed by the German pharmaceutical company, Boehringer Ingelheim Pharma KG.[1]
Quick Facts Clinical data, Routes ofadministration ...
![]() Structure of Otenzepad | |
Clinical data | |
---|---|
Routes of administration | oral |
Pharmacokinetic data | |
Bioavailability | 45% (oral)[1] |
Elimination half-life | 2.5h |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.220.541 ![]() |
Chemical and physical data | |
Formula | C24H31N5O2 |
Molar mass | 421.545 g·mol−1 |
3D model (JSmol) | |
| |
|
Close